Yu Chen

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
  2. pmc Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Yu Chen
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 10:981-91. 2009
  3. pmc ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
    Yu Chen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 19:1023-9. 2013
  4. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
  5. pmc ARN-509: a novel antiandrogen for prostate cancer treatment
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 72:1494-503. 2012
  6. pmc Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
    Brett S Carver
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:575-86. 2011
  7. pmc ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
  8. pmc β4 Integrin signaling induces expansion of prostate tumor progenitors
    Toshiaki Yoshioka
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, USA
    J Clin Invest 123:682-99. 2013
  9. pmc Overcoming mutation-based resistance to antiandrogens with rational drug design
    Minna D Balbas
    Louis V Gerstner, Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, United States Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
    elife 2:e00499. 2013
  10. doi request reprint Acute uremia suppresses leucine-induced signal transduction in skeletal muscle
    Kevin L McIntire
    1 Research Service, Veterans Affairs Palo Alto Health Care System VAPAHCS, Palo Alto, California, USA 2 Renal Division, Department of Medicine, Stanford University, Stanford, California, USA
    Kidney Int 85:374-82. 2014

Collaborators

Detail Information

Publications15

  1. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  2. pmc Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Yu Chen
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 10:981-91. 2009
    ..Both agents are undergoing phase 3 testing. Here, we review the basic science and clinical development of these and other agents...
  3. pmc ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
    Yu Chen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 19:1023-9. 2013
    ..We propose that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss. ..
  4. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
    ..Many of these strategies are currently being tested in clinical trials in CRPC...
  5. pmc ARN-509: a novel antiandrogen for prostate cancer treatment
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 72:1494-503. 2012
    ..Our findings offer preclinical proof of principle for ARN-509 as a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer...
  6. pmc Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
    Brett S Carver
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:575-86. 2011
    ....
  7. pmc ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
    ..It also represents a novel mechanism of oncogenic transcription factor activation...
  8. pmc β4 Integrin signaling induces expansion of prostate tumor progenitors
    Toshiaki Yoshioka
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, USA
    J Clin Invest 123:682-99. 2013
    ..These findings indicate that the β4 integrin promotes prostate tumorigenesis by amplifying ErbB2 and c-Met signaling in tumor progenitor cells...
  9. pmc Overcoming mutation-based resistance to antiandrogens with rational drug design
    Minna D Balbas
    Louis V Gerstner, Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, United States Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
    elife 2:e00499. 2013
    ..DOI:http://dx.doi.org/10.7554/eLife.00499.001...
  10. doi request reprint Acute uremia suppresses leucine-induced signal transduction in skeletal muscle
    Kevin L McIntire
    1 Research Service, Veterans Affairs Palo Alto Health Care System VAPAHCS, Palo Alto, California, USA 2 Renal Division, Department of Medicine, Stanford University, Stanford, California, USA
    Kidney Int 85:374-82. 2014
    ..Thus, leucine resistance, together with the reduction in IGF-1 and increase in IL-6 expression, may explain why the anabolic effect of nutritional therapy is diminished in acute uremic patients. ..
  11. doi request reprint Prostate cancer in 2011: Hitting old targets better and identifying new targets
    Yu Chen
    Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 9:70-2. 2012
    ..These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies...
  12. doi request reprint CD39 modulates hematopoietic stem cell recruitment and promotes liver regeneration in mice and humans after partial hepatectomy
    Moritz Schmelzle
    Department of Medicine, Liver Center and Transplantation Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA02115, USA
    Ann Surg 257:693-701. 2013
    ..To study molecular mechanisms involved in hematopoietic stem cell (HSC) mobilization after liver resection and determine impacts on liver regeneration...
  13. doi request reprint Uremia attenuates growth hormone-stimulated insulin-like growth factor-1 expression, a process worsened by inflammation
    Yu Chen
    Department of Medicine, Stanford University, Stanford, California, USA
    Kidney Int 78:89-95. 2010
    ..Thus, our findings indicate that hepatic resistance to GH-induced IGF-1 expression in uremia arises due to defects in STAT5b phosphorylation and its impaired binding to DNA, processes further aggravated by inflammation...
  14. pmc Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers
    Yu Chen
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 17:415-6. 2010
    ..There is an extraordinary degree of overlap between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation and promotes EZH2-mediated dedifferentiation...
  15. ncbi request reprint In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1
    Asha Rajagopal
    Laboratory of Cellular Biophysics, The Rockefeller University, New York, New York 10021, USA
    Cancer Res 62:391-6. 2002
    ..Additionally, MRP1-EGFP expression protected cells from the microtubule depolymerization caused by vincristine and colchicine, but not by vinblastine...